Clinical Research Directory
Browse clinical research sites, groups, and studies.
TCR-T Cell Immunotherapy of Lung Cancer and Other Solid Tumors
Sponsor: Second Affiliated Hospital of Guangzhou Medical University
Summary
Tumor organoids and TILs (and/or peripheral T cells) cultures will be established from fresh tissure of lung cancer and other solid tumors. Coculture will be utilized to screen tumor-responsive T cells which are further selected for monoclonal expansion and TCR cloning for engineered reconstitution of TCR-T cells. After verification by multiple in vitro and in vivo studies, a large number of TCR-T cells will be introduced back into the patients via vein, artery or fine needle punctured to the tumor, or combinations. In this phase I study, the safety, tolerance and preliminary efficacy of the TCR-T cell immunotherapy on human will firstly be assessed.
Official title: TCR-T Cells Targeting Cancer Cells for Immunotherapy of Lung Cancer and Other Solid Tumors: Phase I Clinical Trial
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
30
Start Date
2018-12-01
Completion Date
2036-12-30
Last Updated
2024-06-25
Healthy Volunteers
No
Interventions
TCR-T cells
Engineering TCR-T cells targeting lung tumor and other solid tumor will be transfused back the patients.
Locations (1)
The Second Affiliated Hospital of Guangzhou Medical University
Guanzhou, Guangdong, China